Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New toolkit aims to keep HIV patients on track

NCT ID NCT07439003

Disease control Sponsor: Boston University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to help people with HIV stay in care, especially during the first six months of treatment when the risk of dropping out is highest. Researchers will create and test a toolkit that includes risk assessments, a treatment roadmap, and a WhatsApp support coach. The study will involve up to 30,000 patients and 90 providers at clinics in South Africa. The goal is to improve attendance at follow-up visits and reduce treatment interruptions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15,270 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Groups 1 and 2 will comprise ART clients initiating or re-initiating ART or on ART at one of the study sites during the pilot evaluation period. Group 3 will comprise healthcare providers at the study sites who were exposed to the intervention (implemented the retention toolkit).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group 1: * ≥18 years old at treatment initiation or re-initiation * Initiating ART (newly or re-engaging after a period of interruption) or currently receiving ART at one of the participating study sites. Group 2: * Seeking care at an intervention site during their early treatment period * Reachable at telephone (mobile) number provided * Consented to participate in qualitative data collection Group 3: * Employed by DOH or an implementing partner at a study site * Trained and participated in delivering the intervention * Consented to participate in qualitative data collection Exclusion Criteria: No exclusion criteria for any group.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Health Economics and Epidemiology Research Office

    RECRUITING

    Johannesburg, Gauteng, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.